{"contentid": 488032, "importid": NaN, "name": "Cheaper cancer drug battle stoked up in India", "introduction": "As India's Biocon Biologics partners pharma giants Novartis and Pfizer to enhance access to life-saving cancer drugs for patients, especially in Sub-Saharan and Asian regions, several Indian drug majors are ponying up to ensure easy access to top cancer drugs, reports The Pharma Letter\u00e2\u0080\u0099s India correspondent.", "content": "<p>As India's Biocon Biologics (BSE: 53223) partners pharma giants Novartis (NOVN: VX) and Pfizer (NYSE: PFE) to enhance access to life-saving cancer drugs for patients, especially in Sub-Saharan and Asian regions, several Indian drug majors are ponying up to ensure easy access to top cancer drugs, reports The Pharma Letter&rsquo;s India correspondent.</p>\n<p>The battle for cheaper cancer drugs has ratcheted up in India with the Central Drugs Standard Control Organization (CDSCO) recently approving several generic versions of sunitinib to treat kidney cancer.&nbsp;</p>\n<p>The approval of generic brands of expensive oncology drugs is set to help in reducing the cost of these life-saving drugs, and improve access and adherence to treatment in the future.</p>\n<p>Oncology is a key driver for growth of the Indian pharmaceutical industry and is estimated to account for about 30% of its product pipeline and 25% of pharmaceutical industry revenue by 2021. The Indian market is undergoing significant growth due to the factors such as the rising prevalence of different cancers, increasing new drug launch and product approvals.</p>\n<h2><strong>India: new battleground</strong></h2>\n<p>Union Health minister Dr Harsh Vardhan recently noted that, with some bold initiatives, the cost of cancer drugs and cancer care could be managed in such a way to improve outcomes for patients through greater accessibility and affordability of drugs and still allow for continued pharmaceutical innovation.</p>\n<p>Dr Vardhan was speaking at the launch of the upcoming second campus of the Rajiv Gandhi Center for Biotechnology (RGCB) at Akkulam in Thiruvananthapuram. The campus is to be developed as a major facility on translational applications of immunotherapy and development of therapeutic antibodies for the treatment of cancer.</p>\n<p>Dr Vardhan said RGCB&rsquo;s close association with multiple cancer hospitals in Kerala is a good model that is expected to facilitate the advanced cell-based therapy against cancer at affordable costs to needy patients.</p>\n<p>A lead anticancer molecule discovered by RGCB team has been licensed to a multinational company and is in the final stages of preclinical testing at Oklahoma Medical Research Foundation, USA.</p>\n<h2><strong>Home front</strong></h2>\n<p>Shares of AstraZeneca&rsquo;s (LSE AZN) Indian unit gained nearly 2% in opening deals on the Bombay Stock Exchange on Friday after the drugmaker received import and market permission from the Drugs Controller General of India (DCGI) for osimertinib tablets (Tagrisso) used in the treatment of non-small cell lung cancer.&nbsp;</p>\n<p>\"Osimertinib tablets as monotherapy is now approved for additional indication for the adjuvant treatment after complete tumor resection in patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations,\" the company said.</p>\n<p>The approval paves the way for the launch of osimertinib tablets into a new disease area in India. Last October, AstraZeneca Pharma India launched its acalabrutinib 100mg capsules, used for the treatment of various types of blood cancers, under the brand name Calquence in the country.</p>\n<p>India's Natco Pharma (BSE: 524816) announced that its marketing partner, Breckenridge Pharmaceutical (BPI), received final approval for its abbreviated new drug application (ANDA) for everolimus tablets (a generic version of Afinitor) from the US Food and Drug Administration. BPI plans to launch 2.5mg, 5mg and 7.5mg strengths of the product shortly.</p>\n<p>As per industry sales data, cancer drug Afinitor and its therapeutic equivalents generated annual sales of $712 million in USA during the 12 months ending December 2020.</p>\n<p>While Natco aims to launch around 10 new products every year in the Indian market, Shilpa Medicare has launched sunitinib capsules, under the brand name Sunishil.&nbsp;</p>\n<p>Sunitinib is a novel oral multi targeted tyrosine kinase inhibitor with anti-tumour and antiangiogenic activities. Sunitinib capsules are indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib, advanced renal cell carcinoma.</p>\n<p>Shilpa Medicare's sunitinib capsules has been proven to be bioequivalent to international brand Sutent capsules of Pfizer.</p>\n<p>Bengaluru-based Biocon recently announced a partnership with international organizations to enhance access to its life-saving cancer medicines in lower and middle-income countries. With this, the Indian company, has joined the list of companies, including Novartis, Pfizer, and Viatris, which distribute its drugs at subsidized prices and increase their access.&nbsp;</p>\n<p>Through the partnership, Biocon Biologics aims to enhance access to lifesaving cancer therapies, including biologic trastuzumab and biologic pegfilgrastim. The expanded partnership is to make 26 medicines in 39 formulations affordably available to low- and middle-income countries across Africa and Asia, including key chemotherapies, hormonal therapies, biologics, and supportive therapies essential for the treatment of 30 cancers, including breast cancer.</p>\n<p>Last October, Lupin (BSE: 500257) launched lapatinib tablets, for advanced or metastatic breast cancer, in the US market. The company launched the tablets after its alliance partner Natco Pharma received final approval for its ANDA from the US FDA.&nbsp;</p>\n<p>The product is a generic version of Novartis&rsquo; Tykerb tablets. According to IQVIA MAT June 2020 data, lapatinib tablets had annual sales of approximately $61 million in the US.</p>\n<h2><strong>Generic drugs</strong></h2>\n<p>According to GlobalData, 1,351 generic drugs are available in India for the treatment of different cancers, as of 26 February 2021. The approval of several generic versions of sunitinib to treat kidney cancer by the CDSCO is a case in point.&nbsp;</p>\n<p>While Glenmark Pharmaceuticals (BSE: 532296) recently launched Sutib, the generic version of sunitinib oral capsules to treat kidney cancer in India, generic companies Beta Drugs also launched sunitinib generic with brand name Adsunib. Other companies with sunitinib generics include Globela Pharma and SP Accure Labs.</p>\n<p>In 2020, Zydus Cadila (BOM: 532321) launched a generic brand of enzalutamide Obnyx for prostate cancer, reducing the monthly treatment cost by 70%. Several other companies too had launched enzalutamide generics in India.&nbsp;</p>\n<p>Similarly, the launch of dasatinib generics reduced the monthly treatment cost for chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) by more than 96% compared to originator brand drug cost.</p>\n<p class=\"filename\">Image: india_large_credit_deposit_photos</p>\n<p>&nbsp;</p>", "date": "2021-03-15 10:31:00", "meta_title": "Cheaper cancer drug battle stoked up in India", "meta_keywords": "Cancer drugs, Generics, CDSCO, Approvals. AstraZeneca, Tagrisso, Biocon, Pegfilgrastim, Traztuzumab, Natco, Afinitor", "meta_description": "Cheaper cancer drug battle stoked up in India", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-14 12:16:11", "updated": "2021-03-16 12:10:31", "access": NaN, "url": "https://www.thepharmaletter.com/article/cheaper-cancer-drug-battle-stoked-up-in-india", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "india_big.jpg", "image2id": "india_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biosimilars, Generics", "therapy area_tag": "Oncology", "topic_tag": "Focus On, From our correspondent, In Depth, Pricing, reimbursement and access, Product Launch, Regulation", "geography_tag": "India", "company_tag": "AstraZeneca, Biocon, Natco Pharma", "drug_tag": "Afinitor, pegfilgrastim, trastuzumab", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-15 10:31:00"}